Physician profile
Daniel Bonville
NPI 1639286602
$28,089.09
in general payments reported to CMS, 2019-2025
21 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,181 · 2021: $1,037 · 2022: $5,726 · 2023: $1,765 · 2024: $2,207 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014 · Travel and Lodging: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.53 |
| Travel and Lodging | $1,205.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,937.75 | 2019-2024 | Da Vinci Surgical System |
| Tela Bio, INC. | $4,336.77 | 2019-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Medical Device Business Services, INC. | $4,275.60 | 2022-2024 | Matrixrib |
| Zimmer Biomet Holdings, INC. | $1,373.87 | 2022-2024 | Advantagerib, Ribfix Blu Advantage |
| Imbed Biosciences INC. | $994.18 | 2023 | |
| Medtronic USA, INC. | $893.86 | 2020 | |
| Aroa Biosurgery Incorporated | $486.11 | 2023-2024 | |
| Wound Management Technologies, INC | $377.14 | 2019 | |
| Atricure, INC. | $266.66 | 2022 | |
| Medtronic, INC. | $246.90 | 2025 | Ligasure |
| Depuy Synthes Sales INC. | $236.32 | 2019-2022 | |
| Sanara Medtech INC. | $150.69 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $143.85 | 2021 | |
| Acell, INC. | $92.41 | 2019 | |
| Avanos Medical | $80.97 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $62.30 | 2021 | |
| Smith+Nephew, INC. | $34.64 | 2024 | Grafix Pl, Stravix Pl, Oasis Micro |
| Davol INC. | $32.87 | 2022 | |
| Allergan, INC. | $25.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.34 | 2022 | |
| Boston Scientific Corporation | $18.86 | 2023 | Spyglass |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bonville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.